Smartleaf Asset Management’s Amylyx Pharmaceuticals AMLX Stock Holding History

Smartleaf Asset Management’s Portfolio AMLX Stock Details AMLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$2.93K	Buy	+100	New	+$2.65K	﹤0.01%	2915

Other funds holding AMLX

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.23B AUM 121.47% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

Smartleaf Asset Management's AMLX Position: Q3 2026 in Review

Smartleaf Asset Management opened a new position in Amylyx Pharmaceuticals (AMLX) in Q3 2026: 100 shares worth $2.93K. The stake represents ﹤0.01% of the portfolio and ranks #2915 among its holdings.

147 funds tracked by Wall St. Rank hold AMLX as of Q3 2026.

Smartleaf Asset Management held 100 shares of Amylyx Pharmaceuticals worth $2.93K as of Q3 2026.
Amylyx Pharmaceuticals was a new Smartleaf Asset Management position in Q3 2026.
Amylyx Pharmaceuticals made up ﹤0.01% of Smartleaf Asset Management's portfolio in Q3 2026, its #2915 holding.
147 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q3 2026.

Based on Smartleaf Asset Management's 13F filing for Q3 2026, filed 10 Nov 2026.